Researchers Discover Potential Marker to Better Identify, Resect Glioblastoma Multiforme Tumors

Released: 20-Mar-2014 4:00 PM EDT
Embargo expired: 7-Apr-2014 1:40 PM EDT
Source Newsroom: American Association of Neurological Surgeons (AANS)
Contact Information

Available for logged-in reporters only

Citations 82nd Annual Scientific Meeting of the American Association of Neurological Surgeons

Newswise — SAN FRANCISCO (April 7, 2014) — Glioblastoma multiforme (GBM) has a history of invasive growth, often extending into neural tissue well beyond MRI contrast-enhancement margins. During a presentation during the 82nd Annual Scientific Meeting of the American Association of Neurological Surgeons (AANS), Jan Coburger, MD, highlighted the results of research that explores whether 5 aminolevulinic-acid fluorescence (5-ALA) offers additional detection benefits compared to intraoperative MRI (iMRI) when dealing with invasive tumors.

For the study 5-Aminoleyulinic acid fluorescence exceeds Gd-DTPA enhanced intraoperative MRI in tumor detection at the border of glioblastoma multiforme: A prospective study based on histopathological assessment, researchers enrolled 34 patients harboring a GBM with intended gross total resection. All patients had surgery using iMRI and 5-ALA guided resection following a specific protocol. A white-light tumor resection was performed first, then spatial location of residual fluorescence was subsequently marked. After that, an iMRI was performed and residual uptake of contrast was marked and navigated biopsies were taken from these areas and from additional areas. Correlations of histopathological findings with imaging results were tested using Spearman’s rho.

The researchers found that imaging results of 5-ALA and iMRI were significantly different at the border zone of GBMs, and that 5-ALA has a higher sensitivity and a lower specificity for tumor detection than Gd-DTPAenhanced iMRI. They concluded that for detection of infiltrating tumors, 5-ALA is superior to Gd-DTPA-enhanced iMRI concerning both sensitivity and specificity.

Study co-authors are Jens Engelke, MD; Angelika Scheuerle, MD; Dietmar Thal, MD, PhD; Michal Hlavac, MD; Thomas Kretschmer, MD, PhD; Christian Wirtz, MD, PhD; and Ralph König, MD, PhD.

Disclosure: The author reported no conflicts for disclosure.

Media Representatives: The 2014 AANS Annual Meeting Press Kit includes releases on highlighted scientific research, AANS officer and award winners, National Neurosurgery Awareness Week, and other relevant information about this year’s program. Those releases also will be posted under the Media area on the 2014 AANS Annual Scientific Meeting website (http://www.aans.org/Annual Meeting/2014/Main/Media.aspx). If you would have interest in a topic related to neurosurgery or would like to interview a neurosurgeon — either onsite or via telephone — during this year’s event, please contact John Iwanski, AANS Director of Integrated Marketing and Website Communications, via the onsite press room at 415.978.3603 or e-mail him at jai@aans.org.

About the 2014 AANS Annual Scientific Meeting: Attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals, the AANS Annual Scientific Meeting is the largest gathering of neurosurgeons in the nation, with an emphasis on the field’s latest research and technological advances. A record-breaking 1,321 scientific abstracts were presented for review at the 2014 AANS Annual Scientific Meeting, and the scientific presentations given at this year’s event represent cutting-edge examples of the incredible developments taking place within the field of neurosurgery. Additional information about the AANS Annual Scientific Meeting and the Meeting Program can be found at http://www.aans.org/Annual Meeting/2014/Main/Home.aspx.

Founded in 1931 as the Harvey Cushing Society, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with nearly 8,600 members worldwide. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public. All active members of the AANS are certified by the American Board of Neurological Surgery, the Royal College of Physicians and Surgeons (Neurosurgery) of Canada or the Mexican Council of Neurological Surgery, AC. Neurological surgery is the medical specialty concerned with the prevention, diagnosis, treatment and rehabilitation of disorders that affect the entire nervous system including the spinal column, spinal cord, brain and peripheral nerves. For more information, visit www.AANS.org.

###


Comment/Share